Benefit from Almonertinib after Osimertinib treat EGFR 19 exon deletion NSCLC induced Severe rash: a case report

Abstract

Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), has been recommended as a first-line treatment of EGFR-positive non-small cell lung cancer (NSCLC). Skin rash is one of the most common side effects of osimertinib, and can have an impact on patients’ quality of life and follow-up. However, there are few reports on the safety and efficacy of switching therapy with osimertinib and the other three generations of TKIs. In this paper, we present a case of NSCLC with an EGFR exon 19 deletion (19del) and MET gene amplification who developed a severe rash after 2 months of treatment with osimertinib that did not recur after switching to replacement therapy with aumonertinib. Our findings indicate that aumonertinib is as effective as osimertinib in treating EGFR19del, while also exhibiting a lower occurrence of adverse skin reactions. This may result in an improved quality of life for patients.

Keywords:

• Aumonertinib
• Osimertinib
• non-small cell lung cancer (NSCLC)
• rash
• eGFR
• treatment

Acknowledgments

The authors greatly appreciate Yu Song of the University of Lanzhou of the First School of Clinical Medicine for her helpful contribution to language editing assistance.

Study approval statement

The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All procedures performed in this study were in accordance with the ethical standards of the institutional and/or national research committee(s) and with the Helsinki Declaration (as revised in 2013).

Consent to publish statement

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. We have made the best efforts to contact the relative and the article has been sufficiently anonymized to cause no harm to the patient or his or her family.

Author contributions

1. Conception and design: Qichen Zhang, Hui Qiao.

2. Administrative support: Hui Qiao.

3. Provision of study materials or patients: Hui Qiao.

4. Collection and assembly of data: Hui Qiao, Peng Xie, Xiaoming Hou, Chengpeng Zhao, Ling Duan.

5. Data analysis and interpretation: Qichen Zhang, Hui Qiao.

6. Manuscript writing: All authors.

7. Final approval of manuscript: All authors.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This work was supported by the Organization Department of CPC Gansu provincial Party committee under Grant 2022LQTD24; Lanzhou Science and Technology Bureau under Grant 2023-4-17; and Gansu Provincial Department of Science and Technology under Grant 21JR7RA390.